ARTICLE | Clinical News
Palosuran: Development discontinued
May 30, 2005 7:00 AM UTC
ATLN discontinued development of palosuran after preliminary data did not show efficacy as measured by markers of kidney function. The urotensin-II receptor antagonist was in 3 Phase II trials in abou...